Intensive short‐term chemotherapy regimen induces high remission rate (over 90%) and event‐free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemiaGiuseppe Todeschini, Giovanni Pizzolo, Massimiliano Bonifacio et al.|American Journal of Hematology|2011Cited by 32
Incorporation of Thalidomide into Up-Front Double Autologous Stem-Cell Transplantation (ASCT) for Multiple Myeloma Improves the Outcome in Comparison with Double ASCT without Thalidomide. Analysis of Baseline Factors Predicitve of Outcome.Elena Zamagni, Michèle Cavo, Nicoletta Testoni et al.|Blood|2007Cited by 3
Secondary Genetic Events and Their Relationship to TP53 Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL)Maria Elena Carazzolo, Carlo Visco, Vittorio Ruggero Zilioli et al.|Cancers|2025Cited by 1
A COMPLETELY GENETIC PROGNOSTIC MODEL OVERCOMES CLINICAL PROGNOSTICATORS IN MANTLE CELL LYMPHOMA: RESULTS FROM THE MCL0208 TRIAL FROM THE FONDAZIONE ITALIANA LINFOMI (FIL)Simone Ferrero, Francesco Bertoni, Riccardo Moia et al.|Hematological Oncology|2021Cited by 0
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trialRiccardo Moia, Simone Ferrero, Simone Ragaini et al.|Leukemia|2025Cited by 0